Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GBA1-Associated Parkinson's Disease Is a Distinct Entity.

International journal of molecular sciences - 28 Jun 2024

Skrahin Aliaksandr, Horowitz Mia, Istaiti Majdolen, Skrahina Volha, Lukas Jan, Yahalom Gilad, Cohen Mikhal E, Revel-Vilk Shoshana, Goker-Alpan Ozlem, Becker-Cohen Michal, Hassin-Baer Sharon, Svenningsson Per, Rolfs Arndt, Zimran Ari

Abstract excerpt

GBA1-associated Parkinson's disease (GBA1-PD) is increasingly recognized as a distinct entity within the spectrum of parkinsonian disorders. This review explores the unique pathophysiological features, clinical progression, and genetic underpinnings that differentiate GBA1-PD from idiopathic Parkinson's disease (iPD). GBA1-PD typically presents with earlier onset and more rapid progression, with a poor response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Glucosylceramidase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Parkinson Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 39000225
DOI: 10.3390/ijms25137102
PMCID: PMC11241486

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GBA1-Associated Parkinson's Disease Is a Distinct Entity.PMID 39000225Read ↗

The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson's Disease: a New Genetic State of the Art.Semantic proximity Read ↗

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease.Semantic proximity Read ↗

Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.Semantic proximity Read ↗

GBA1-associated parkinsonism: new insights and therapeutic opportunitiesSemantic proximity Read ↗

GBA Variants and Parkinson Disease: Mechanisms and Treatments.Semantic proximity Read ↗

GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted TherapySemantic proximity Read ↗

Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.Semantic proximity Read ↗

Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.Semantic proximity Read ↗

Multi-omics insights into GBA1-associated Parkinson's disease: interplay of genomics, transcriptomics, proteomics, and lipidomics.Semantic proximity Read ↗

[GBA mutations and Parkinson's disease].Semantic proximity Read ↗

GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic ApproachesSemantic proximity Read ↗

The link between the GBA gene and parkinsonism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.